Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

@inproceedings{Verhoef2017AssociationBQ,
  title={Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study},
  author={Gregor E. G. Verhoef and Tadeusz Robak and Hui-qiang Huang and Halyna Pylypenko and Noppadol Siritanaratkul and Juliana Pereira and Johannes Drach and Jiř{\'i} Mayer and Rumiko Okamoto and Lixia Pei and Brendan Rooney and Andrew Cakana and Helgi J K van de Velde and Franco Cavalli},
  booktitle={Haematologica},
  year={2017}
}
In the phase 3 LYM-3002 study comparing intravenous VR-CAP with R-CHOP in patients with newly-diagnosed, measurable stage II-IV mantle cell lymphoma, not considered or ineligible for transplant, the median progression-free survival was significantly improved with VR-CAP (24.7 versus 14.4 months with R-CHOP; P<0.001). This post-hoc analysis evaluated the association between the improved outcomes and quality of responses achieved with VR-CAP versus R-CHOP in LYM-3002. Patients were randomized to… CONTINUE READING